Cargando…
Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter
The coronavirus disease 2019 (COVID-19) pandemic has a serious impact on health and economics worldwide. Even though the majority of patients present with moderate and mild symptoms, yet a considerable portion of patients need to be treated in the intensive care unit. Aside from dexamethasone, there...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046512/ https://www.ncbi.nlm.nih.gov/pubmed/33870077 http://dx.doi.org/10.1055/s-0041-1727121 |
_version_ | 1783678866490916864 |
---|---|
author | Pape, Anke Kielstein, Jan T. Krüger, Tillman Fühner, Thomas Brunkhorst, Reinhard |
author_facet | Pape, Anke Kielstein, Jan T. Krüger, Tillman Fühner, Thomas Brunkhorst, Reinhard |
author_sort | Pape, Anke |
collection | PubMed |
description | The coronavirus disease 2019 (COVID-19) pandemic has a serious impact on health and economics worldwide. Even though the majority of patients present with moderate and mild symptoms, yet a considerable portion of patients need to be treated in the intensive care unit. Aside from dexamethasone, there is no established pharmacological therapy. Moreover, some of the currently tested drugs are contraindicated for special patient populations like remdesivir for patients with severely impaired renal function. On this background, several extracorporeal treatments are currently explored concerning their potential to improve the clinical course and outcome of critically ill patients with COVID-19. Here, we report the use of the Seraph 100 Microbind Affinity filter, which is licensed in the European Union for the removal of pathogens. Authorization for emergency use in patients with COVID-19 admitted to the intensive care unit with confirmed or imminent respiratory failure was granted by the U.S. Food and Drug Administration on April 17, 2020. A 53-year-old Caucasian male with a severe COVID-19 infection was treated with a Seraph Microbind Affinity filter hemoperfusion after clinical deterioration and commencement of mechanical ventilation. The 70-minute treatment at a blood flow of 200 mL/minute was well tolerated, and the patient was hemodynamically stable. The hemoperfusion reduced D-dimers dramatically. This case report suggests that the use of Seraph 100 Microbind Affinity filter hemoperfusion might have positive effects on the clinical course of critically ill patients with COVID-19. However, future prospective collection of data ideally in randomized trials will have to confirm whether the use of Seraph 100 Microbind Affinity filter hemoperfusion is an option of the treatment for COVID-19. |
format | Online Article Text |
id | pubmed-8046512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-80465122021-04-15 Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter Pape, Anke Kielstein, Jan T. Krüger, Tillman Fühner, Thomas Brunkhorst, Reinhard TH Open The coronavirus disease 2019 (COVID-19) pandemic has a serious impact on health and economics worldwide. Even though the majority of patients present with moderate and mild symptoms, yet a considerable portion of patients need to be treated in the intensive care unit. Aside from dexamethasone, there is no established pharmacological therapy. Moreover, some of the currently tested drugs are contraindicated for special patient populations like remdesivir for patients with severely impaired renal function. On this background, several extracorporeal treatments are currently explored concerning their potential to improve the clinical course and outcome of critically ill patients with COVID-19. Here, we report the use of the Seraph 100 Microbind Affinity filter, which is licensed in the European Union for the removal of pathogens. Authorization for emergency use in patients with COVID-19 admitted to the intensive care unit with confirmed or imminent respiratory failure was granted by the U.S. Food and Drug Administration on April 17, 2020. A 53-year-old Caucasian male with a severe COVID-19 infection was treated with a Seraph Microbind Affinity filter hemoperfusion after clinical deterioration and commencement of mechanical ventilation. The 70-minute treatment at a blood flow of 200 mL/minute was well tolerated, and the patient was hemodynamically stable. The hemoperfusion reduced D-dimers dramatically. This case report suggests that the use of Seraph 100 Microbind Affinity filter hemoperfusion might have positive effects on the clinical course of critically ill patients with COVID-19. However, future prospective collection of data ideally in randomized trials will have to confirm whether the use of Seraph 100 Microbind Affinity filter hemoperfusion is an option of the treatment for COVID-19. Georg Thieme Verlag KG 2021-04-14 /pmc/articles/PMC8046512/ /pubmed/33870077 http://dx.doi.org/10.1055/s-0041-1727121 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Pape, Anke Kielstein, Jan T. Krüger, Tillman Fühner, Thomas Brunkhorst, Reinhard Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter |
title | Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter |
title_full | Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter |
title_fullStr | Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter |
title_full_unstemmed | Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter |
title_short | Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter |
title_sort | treatment of a critically ill covid-19 patient with the seraph 100 microbind affinity filter |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046512/ https://www.ncbi.nlm.nih.gov/pubmed/33870077 http://dx.doi.org/10.1055/s-0041-1727121 |
work_keys_str_mv | AT papeanke treatmentofacriticallyillcovid19patientwiththeseraph100microbindaffinityfilter AT kielsteinjant treatmentofacriticallyillcovid19patientwiththeseraph100microbindaffinityfilter AT krugertillman treatmentofacriticallyillcovid19patientwiththeseraph100microbindaffinityfilter AT fuhnerthomas treatmentofacriticallyillcovid19patientwiththeseraph100microbindaffinityfilter AT brunkhorstreinhard treatmentofacriticallyillcovid19patientwiththeseraph100microbindaffinityfilter |